Five-year follow-up results of thermal ablation for low-risk papillary thyroid microcarcinomas: systematic review and meta-analysis

Cho, Se Jin; Baek, Sun Mi; Na, Dong Gyu; Lee, Kang Dae; Shong, Young Kee; Baek, Jung Hwan

doi:10.1007/s00330-021-07808-x

Cited by 39 publications

(19 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42 Since tumor volume typically decreases gradually over time, another meta-analysis with a longer follow-up period of 60 to 72 months showed better efficacy with a VRR of 99.4% and a pooled disappearance rate of 98.5%. 43 This study had similar efficacy. During the median follow-up of 77.2 months, the median VRR was 100%, and 99.4% of the tumors radiographically disappeared.…”

Section: Discussionsupporting

confidence: 53%

“…A meta-analysis (1770 patients, 1822 PTMCs) with a mean follow-up period of 33.0±11.4 months, reported the pooled proportion of VRR at 12 months was 92.1% and the pooled disappearance rate was 79% 42. Since tumor volume typically decreases gradually over time, another meta-analysis with a longer follow-up period of 60 to 72 months showed better efficacy with a VRR of 99.4% and a pooled disappearance rate of 98.5% 43. This study had similar efficacy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term Outcomes of Ultrasound-guided Thermal Ablation for the Treatment of Solitary Low-risk Papillary Thyroid Microcarcinoma

Yan

Liu

et al. 2023

Annals of Surgery

View full text Add to dashboard Cite

Objective: To report more than 5-year outcomes of ultrasound-guided thermal ablation (TA) for patients with solitary low-risk papillary thyroid microcarcinoma (PTMC) in a large multicenter cohort. Background: TA, including radiofrequency ablation (RFA) and microwave ablation (MWA) have been used in patients with low-risk PTMC who refuse surgery or active surveillance. However, its clinical value remains controversial. Materials and Methods: This retrospective multicenter study included 474 patients with solitary low-risk PTMC treated with TA (357 for RFA; 117 for MWA) from 4 centers and followed up for at least 5 years. Disease progression including lymph node metastasis and recurrent tumors, volume reduction rate (VRR), tumor disappearance rate, complications, and delayed surgery were assessed. RFA and MWA outcomes were compared using propensity score matching. Results: During the median follow-up period of 77.2 months, disease progression incidence, lymph node metastasis, and recurrent tumors rates were 3.6%, 1.1%, and 2.5%, respectively. Age below 40 years old, male sex, Hashimoto thyroiditis, and tumor size were not independent factors associated with disease progression by Cox analysis. The median VRR was 100% and 471 tumors disappeared radiographically. Eight patients experienced transient voice change (1.7%) which recovered within 3 months. None of the patients underwent delayed surgery because of anxiety. After 1:1 matching, no significant differences were found in the disease progression, VRR, tumor disappearance rate, or complications between RFA and MWA subgroups. Conclusion: This multicenter study revealed that TA was an effective and safe treatment for patients with solitary low-risk PTMC, which could be offered as a treatment option for the management for low-risk PTMC.

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

Long-term Outcomes of Ultrasound-guided Thermal Ablation for the Treatment of Solitary Low-risk Papillary Thyroid Microcarcinoma

Yan

Liu

et al. 2023

Annals of Surgery

View full text Add to dashboard Cite

show abstract

“…In another study, 37 patients with PTMC were followed up for 12 months, and the VRR and recurrence rate was 99.34 ± 3.49 and 0%, respectively [8]. In recent years, several meta-analyses have confirmed that thermal ablation is an excellent method for regional tumor control in patients with low-risk PTMC [9]. The management of PTMC is a growing area of interest.…”

Section: Introductionmentioning

confidence: 99%

Long-term follow-up results of PTMC treated by ultrasound-guided radiofrequency ablation: a retrospective study

Ya-lin

Che

Gao

et al. 2021

International Journal of Hyperthermia

View full text Add to dashboard Cite

Objectives: To confirm the long-term efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC). Methods: We retrospectively reviewed data of 102 primary papillary thyroid carcinoma patients (82 women, 20 men; mean age: 43 [19] years) treated with radiofrequency ablation and thyroid-stimulating hormone (TSH) suppression therapy before December 2018. All patients were at high surgical risk or refused surgery. They were followed up at 1, 3, 6, 9, and 12 months and every 6-12 months thereafter using ultrasound and contrast-enhanced ultrasound. The volume and volume reduction ratio was calculated. Recurrence and lymph node or distant metastasis were evaluated. Results: The mean initial tumor diameter was 0.50 (0.29) cm; the mean initial volume was 0.06 (0.09) mL. At 1, 3, 6, 9, 12, 24, 36, 48, and 60 months after RFA, complete resorption rates were 0, 0, 9.8 (10/ 102), 33.3 (34/102), 91.2 (93/102), 96.1 (98/102), 99 (101/102), 100, and 100%, respectively. Two patients had developed ipsilateral neck lymph node metastasis in regions IV and VI at 30-and 18month follow-ups, respectively. After RFA, 3/102 patients (2.9%) developed hoarseness-the main side effect. No life-threatening or delayed complications occurred. The TSH value in the initial period was 0.06 (0.02) mIU/mL; the rate of reaching the TSH target was 85.7%. The TSH value at follow-up was 1.47 (0.91) mIU/mL; the compliance rate was 99.3%. Conclusions: Ultrasound-guided RFA for PTMC is highly effective and safe. RFA can serve as a minimally invasive treatment for PTMC patients who refuse surgery or active surveillance.

show abstract

“…Many studies have confirmed that RFA is effective and safe for treating BTNs ( 17 – 19 ) which the incidence of RFA-associated complications, such as dysphonia, hypocalcemia and bleeding, is very low ( 20 – 22 ). Recent several studies have shown that RFA is effective for treating PTMC ( 23 – 25 ). However, studies on the prognosis, safety, and efficacy of RFA in treating T1N0M0 PTC are still insufficient.…”

Section: Introductionmentioning

confidence: 99%

Efficacy, safety, and controversy of ultrasound-guided radiofrequency ablation in the treatment of T1N0M0 papillary thyroid carcinoma

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo evaluate the safety effect, and controversy on the treatment outcomes of radiofrequency ablation (RFA) for T1N0M0 papillary thyroid carcinoma (PTC).Materials and methodsThis study is assessed the medical records of 142 patients with primary T1N0M0 PTC tumors after RFA between 2014 and 2022. 4 patients underwent delayed surgery (DS) after RFA and 411 T1N0M0 patients underwent DS were recorded. Outcomes were compared between RFA and DS groups after propensity score matching (PSM).ResultsThe maximal diameter (MD) and volume (V) increased in months 1 (P < 0.01) and reduced after the 6-month follow-up (all P < 0.01). The disappearance and disease progression rates were 53.5% and 2.1%, respectively. The complication and disease progression rates had no significant difference between RFA and DS (P>0.05). In some cases, the tumors were not fully inactivated after RFA, and the central compartment lymph node (CCLN) were metastasis. The CCLN metastasis rate was 13.4%. MD, V and clustered calcifications were independent risk factors for CCLN metastasis by univariate analysis.ConclusionsRFA is an effective and safe treatment option in selected patients with solitary T1N0M0 PTC. There are the risks of tumor incompletely ablated and CCLN metastasis.

show abstract

Five-year follow-up results of thermal ablation for low-risk papillary thyroid microcarcinomas: systematic review and meta-analysis

Cited by 39 publications

References 60 publications

Long-term Outcomes of Ultrasound-guided Thermal Ablation for the Treatment of Solitary Low-risk Papillary Thyroid Microcarcinoma

Long-term Outcomes of Ultrasound-guided Thermal Ablation for the Treatment of Solitary Low-risk Papillary Thyroid Microcarcinoma

Long-term follow-up results of PTMC treated by ultrasound-guided radiofrequency ablation: a retrospective study

Efficacy, safety, and controversy of ultrasound-guided radiofrequency ablation in the treatment of T1N0M0 papillary thyroid carcinoma

Contact Info

Product

Resources

About